Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial-Reference-Cited by-同舟云学术

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial

Published:2022-09-17 Issue:11 Volume:39 Page:5229-5243
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Zhou Jiying,Luo Guogang,Xu Yuming,Yang Xiaosu,Pan Xiaoping,Dong Zhao,Zhong Shiying,Liu Hui,Ji Fei,Yu Shengyuan^ORCID

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02291-2.pdf

Reference32 articles.

1. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631–49.

2. Yao C, Wang Y, Wang L, et al. Burden of headache disorders in China, 1990–2017: findings from the Global Burden of Disease Study 2017. J Headache Pain. 2019;20:102.

3. Luo N, Qi W, Zhuang C, et al. A satisfaction survey of current medicines used for migraine therapy in China: is Chinese patent medicine effective compared with Western medicine for the acute treatment of migraine? Pain Med. 2014;15:320–8.

4. Zhao H, Zhang L, Ford J, et al. Treatment patterns and real-world outcomes among patients with episodic migraine in China: results from the Chinese Adelphi Disease Specific Programme. ISPOR Annual Meeting 2021, PND64. https://www.ispor.org/conferences-education/conferences/past-conferences/ispor-2021/program/posters. Accessed 30 Mar 2022.

5. Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action [published correction appears in Neurotherapeutics. 2018 Jan 8]. Neurotherapeutics. 2018;15:274–90.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database;Expert Opinion on Drug Safety;2024-07-10